TCIM
AEGR

TIAA CREF Investment Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

TIAA CREF Investment Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-81,785
Closed -$303K – 3240
2016
Q1 		$303K Hold
81,785
– – ﹤0.01% 2913
2015
Q4 		$826K Hold
81,785
– – ﹤0.01% 2694
2015
Q3 		$1.11M Sell
81,785
-20,171
-20% -$359K ﹤0.01% 2511
2015
Q2 		$1.93M Sell
101,956
-8,026
-7% -$174K ﹤0.01% 2325
2015
Q1 		$2.88M Sell
109,982
-1,909
-2% -$48.6K ﹤0.01% 1995
2014
Q4 		$2.34M Sell
111,891
-4,627
-4% -$117K ﹤0.01% 2129
2014
Q3 		$3.89M Sell
116,518
-2,385
-2% -$74K ﹤0.01% 1796
2014
Q2 		$3.82M Sell
118,903
-158
-0.1% -$5.88K ﹤0.01% 1868
2014
Q1 		$5.49M Sell
119,061
-129,811
-52% -$7.61M ﹤0.01% 1545
2013
Q4 		$17.7M Buy
248,872
+37,557
+18% +$2.87M 0.01% 836
2013
Q3 		$18.1M Buy
211,315
+30,051
+17% +$2.55M 0.01% 794
2013
Q2 		$11.5M Buy
+181,264
New +$9.62M 0.01% 967

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TIAA CREF Investment Management's AEGR Position: Q2 2016 in Review

TIAA CREF Investment Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 81,785 shares — an estimated $303K sold.

TIAA CREF Investment Management first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $18.1M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • TIAA CREF Investment Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 81,785 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $303K.
  • TIAA CREF Investment Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • TIAA CREF Investment Management's Aegerion Pharmaceuticals position peaked at $18.1M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on TIAA CREF Investment Management's 13F filing for Q2 2016, filed 11 Aug 2016.